43 related articles for article (PubMed ID: 9923816)
21. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
Drew L; Fine RL; Do TN; Douglas GP; Petrylak DP
Clin Cancer Res; 2002 Dec; 8(12):3922-32. PubMed ID: 12473608
[TBL] [Abstract][Full Text] [Related]
22. Binding of the epoxide cryptophycin analog, LY355703 to albumin and its effect on in vitro antiproliferative activity.
Schultz RM; Shih C; Wood PG; Harrison SD; Ehlhardt WJ
Oncol Rep; 1998; 5(5):1089-94. PubMed ID: 9683814
[TBL] [Abstract][Full Text] [Related]
23. Biological evaluation of cryptophycin 52 fragment A analogues: effect of the multidrug resistance ATP binding cassette transporters on antitumor activity.
Al-Awar RS; Corbett TH; Ray JE; Polin L; Kennedy JH; Wagner MM; Williams DC
Mol Cancer Ther; 2004 Sep; 3(9):1061-7. PubMed ID: 15367700
[TBL] [Abstract][Full Text] [Related]
24. Antiproliferative mechanism of action of cryptophycin-52: kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends.
Panda D; DeLuca K; Williams D; Jordan MA; Wilson L
Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9313-8. PubMed ID: 9689077
[TBL] [Abstract][Full Text] [Related]
25. A convergent approach to cryptophycin 52 analogues: synthesis and biological evaluation of a novel series of fragment a epoxides and chlorohydrins.
Al-Awar RS; Ray JE; Schultz RM; Andis SL; Kennedy JH; Moore RE; Liang J; Golakoti T; Subbaraju GV; Corbett TH
J Med Chem; 2003 Jul; 46(14):2985-3007. PubMed ID: 12825938
[TBL] [Abstract][Full Text] [Related]
26. The cryptophycins: their synthesis and anticancer activity.
Eggen M; Georg GI
Med Res Rev; 2002 Mar; 22(2):85-101. PubMed ID: 11857635
[TBL] [Abstract][Full Text] [Related]
27. Discovery of cryptophycin-1 and BCN-183577: examples of strategies and problems in the detection of antitumor activity in mice.
Corbett TH; Valeriote FA; Demchik L; Lowichik N; Polin L; Panchapor C; Pugh S; White K; Kushner J; Rake J; Wentland M; Golakoti T; Hetzel C; Ogino J; Patterson G; Moore R
Invest New Drugs; 1997; 15(3):207-18. PubMed ID: 9387043
[TBL] [Abstract][Full Text] [Related]
28. NEW ASPECTS OF THE PHARMACOLOGY OF ANTIMITOTIC AGENTS.
DUSTIN P
Pharmacol Rev; 1963 Sep; 15():449-80. PubMed ID: 14064355
[No Abstract] [Full Text] [Related]
29. B4112, a novel tetramethylpiperidine-substituted phenazine that inhibits the proliferation of multidrug-resistant cancer cell lines.
Van Rensburg CE; Jooné G; Van Niekerk E; Anderson R
Ann N Y Acad Sci; 1999; 886():280-2. PubMed ID: 10667239
[No Abstract] [Full Text] [Related]
30. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines.
Wagner MM; Paul DC; Shih C; Jordan MA; Wilson L; Williams DC
Cancer Chemother Pharmacol; 1999; 43(2):115-25. PubMed ID: 9923816
[TBL] [Abstract][Full Text] [Related]
31. Cryptophycins: a novel class of potent antimitotic antitumor depsipeptides.
Shih C; Teicher BA
Curr Pharm Des; 2001 Sep; 7(13):1259-76. PubMed ID: 11472266
[TBL] [Abstract][Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
